Xpert w MTB/RIF is the most widely used molecular assay for rapid diagnosis of tuberculosis (TB). The number of polymerase chain reaction cycles after which detectable product is generated (cycle threshold value, C T ) correlates with the bacillary burden. O B J E C T I V E : To investigate the association between Xpert C T values and smear status through a systematic review and individual-level data meta-analysis. D E S I G N : Studies on the association between C T values and smear status were included in a descriptive systematic review. Authors of studies including smear, culture and Xpert results were asked for individual-level data, and receiver operating characteristic curves were calculated. R E S U LT S : Of 918 citations, 10 were included in the descriptive systematic review. Fifteen data sets from studies potentially relevant for individual-level data meta-analysis provided individual-level data (7511 samples from 4447 patients); 1212 patients had positive Xpert results for at least one respiratory sample (1859 samples overall). ROC analysis revealed an area under the curve (AUC) of 0.85 (95%CI 0.82-0.87). Cut-off C T values of 27.7 and 31.8 yielded sensitivities of 85% (95%CI 83-87) and 95% (95%CI 94-96) and specificities of 67% and [35] [36] [37] [38] [39] [40] [41] for smear-positive samples. C O N C L U S I O N : Xpert C T values and smear status were strongly associated. However, diagnostic accuracy at set cut-off C T values of 27.7 or 31.8 would not replace smear microscopy. How C T values compare with smear microscopy in predicting infectiousness remains to be seen. K E Y W O R D S : systematic review; diagnosis; Xpert; cycle threshold value THE XPERT w MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay is an automated real-time molecular assay for rapid diagnosis of tuberculosis (TB) and detection [A version in Spanish of this article is available from the Editorial Office in Paris and from the Union website www.theunion.org] nodeficiency virus associated TB. 1 Xpert was first endorsed by the World Health Organization (WHO) in December 2010. In 2013, the WHO recommended that Xpert be used as the initial diagnostic test for all adults and children with signs and symptoms of TB, rather than microscopy and culture. 1,2 A recently updated Cochrane review estimated pooled Xpert sensitivity to be 89% (95% confidence interval [CI] 85-92) and pooled specificity to be 99% (95%CI 98-99). 3 Xpert, which has a lower biohazard risk 4 and is less operator-dependent than conventional smear microscopy, is undergoing a major global roll-out in a number of high-burden countries, and has already replaced smear microscopy in South Africa. 5 The Xpert assay uses molecular beacon technology to detect DNA sequences amplified in a hemi-nested real-time polymerase chain reaction (PCR) assay. The analytical limit of detection of Xpert, defined as the minimum number of bacilli that can be detected with 95% confidence, is 131 (95%CI 106-176) colony forming units per ml of clinical sputum sample. 6,7 Xpert thus has a limit of detection that is 50-100 times greater than that of smear microscopy, and is half as sensitive as liquid culture. 8,9 The assay's cycle threshold value (C T ), which is the number of PCR cycles after which each of the five probes is considered positive, provides a semiquantitative measure of bacillary burden in sputum. 6,10 Mycobacterium tuberculosis bacillary load therefore correlates with smear status, time to culture positivity using liquid culture systems and Xpert C T values. 11 The correlation between smear status and bacillary load as a marker of infectiousness is used to guide public health and treatment decisions. 12 However, smear status provides a rather crude estimate of bacillary burden and can only coarsely dichotomise samples into positive and negative. In settings where smear microscopy is no longer performed, quantitative Xpert C T may be used to identify infectious TB patients for contact tracing as recommended by the WHO. 13 Quantitative Xpert C T values may also help to cost-effectively guide targeted contact tracing of the most infectious TB patients, 14 and thus prioritise contact tracing.
S E T T I N G :
Xpert w MTB/RIF is the most widely used molecular assay for rapid diagnosis of tuberculosis (TB). The number of polymerase chain reaction cycles after which detectable product is generated (cycle threshold value, C T ) correlates with the bacillary burden. O B J E C T I V E : To investigate the association between Xpert C T values and smear status through a systematic review and individual-level data meta-analysis. D E S I G N : Studies on the association between C T values and smear status were included in a descriptive systematic review. Authors of studies including smear, culture and Xpert results were asked for individual-level data, and receiver operating characteristic curves were calculated. R E S U LT S : Of 918 citations, 10 were included in the descriptive systematic review. Fifteen data sets from studies potentially relevant for individual-level data meta-analysis provided individual-level data (7511 samples from 4447 patients); 1212 patients had positive Xpert results for at least one respiratory sample (1859 samples overall). ROC analysis revealed an area under the curve (AUC) of 0.85 (95%CI 0.82-0.87). Cut-off C T values of 27.7 and 31.8 yielded sensitivities of 85% (95%CI [83] [84] [85] [86] [87] and 95% (95%CI 94-96) and specificities of 67% (95%CI [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] and 35% (95%CI [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] for smear-positive samples. C O N C L U S I O N : Xpert C T values and smear status were strongly associated. However, diagnostic accuracy at set cut-off C T values of 27.7 or 31.8 would not replace smear microscopy. How C T values compare with smear microscopy in predicting infectiousness remains to be seen. K E Y W O R D S : systematic review; diagnosis; Xpert; cycle threshold value THE XPERT w MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay is an automated real-time molecular assay for rapid diagnosis of tuberculosis (TB) and detection of rifampicin resistance, recommended for use as the initial diagnostic test in individuals with suspected multidrug-resistant TB (MDR-TB) or human immu-nodeficiency virus associated TB. 1 Xpert was first endorsed by the World Health Organization (WHO) in December 2010. In 2013, the WHO recommended that Xpert be used as the initial diagnostic test for all adults and children with signs and symptoms of TB, rather than microscopy and culture. 1,2 A recently updated Cochrane review estimated pooled Xpert sensitivity to be 89% (95% confidence interval [CI] [85] [86] [87] [88] [89] [90] [91] [92] and pooled specificity to be 99% (95%CI 98-99). 3 Xpert, which has a lower biohazard risk 4 and is less operator-dependent than conventional smear microscopy, is undergoing a major global roll-out in a number of high-burden countries, and has already replaced smear microscopy in South Africa. 5 The Xpert assay uses molecular beacon technology to detect DNA sequences amplified in a hemi-nested real-time polymerase chain reaction (PCR) assay. The analytical limit of detection of Xpert, defined as the minimum number of bacilli that can be detected with 95% confidence, is 131 (95%CI 106-176) colony forming units per ml of clinical sputum sample. 6, 7 Xpert thus has a limit of detection that is 50-100 times greater than that of smear microscopy, and is half as sensitive as liquid culture. 8, 9 The assay's cycle threshold value (C T ), which is the number of PCR cycles after which each of the five probes is considered positive, provides a semiquantitative measure of bacillary burden in sputum. 6, 10 Mycobacterium tuberculosis bacillary load therefore correlates with smear status, time to culture positivity using liquid culture systems and Xpert C T values. 11 The correlation between smear status and bacillary load as a marker of infectiousness is used to guide public health and treatment decisions. 12 However, smear status provides a rather crude estimate of bacillary burden and can only coarsely dichotomise samples into positive and negative. In settings where smear microscopy is no longer performed, quantitative Xpert C T may be used to identify infectious TB patients for contact tracing as recommended by the WHO. 13 Quantitative Xpert C T values may also help to cost-effectively guide targeted contact tracing of the most infectious TB patients, 14 and thus prioritise contact tracing.
The present study investigates the association between Xpert C T values and smear status through a systematic review of the available literature, and a meta-analysis using individual-level data provided by primary studies to establish a receiver operating characteristic (ROC) curve and optimal cut-offs for C T values.
METHOD
The review was conducted according to the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses group (PRISMA). 15 The protocol was registered with PROSPERO (CRD42014013315), 
Inclusion and exclusion criteria
Cohort, cross-sectional, diagnostic studies, prevalence surveys and published and non-published laboratory validation studies were eligible for inclusion if they reported on respiratory samples (spontaneous sputum, induced sputum, broncho-alveolar lavage, tracheal aspirates, pleural fluid) and provided culture (either solid or liquid), microscopy (auramine or Ziehl-Neelsen) and Xpert C T values. Studies were included if all three diagnostic tests (microscopy, culture and Xpert) were performed and if the culture isolate was identified as M. tuberculosis complex using either nucleic-acid amplification test or antigen testing. Studies reporting the association between Xpert C T values and smear status were included in the descriptive analysis. Authors of studies included in the descriptive analysis and authors of studies presenting Xpert, smear microscopy and culture results were contacted and asked to provide individual-level data. Studies were excluded if sample sets were not random or consecutive. We did not exclude studies that assessed patients during treatment.
Search strategy
A search strategy was developed (see Appendix*) to identify all relevant studies, regardless of language or publication status. Medline, Embase, Global Health, Current Controlled Trials and the Cochrane database were searched. All references were imported into EndNote (Thomson Reuters, New York, NY, USA), duplicates were removed and abstracts were examined independently by two reviewers. Full-text articles of all potentially relevant studies were obtained, and inclusion criteria were applied. Studies included in three published reviews investigating the diagnostic accuracy of Xpert were also screened for inclusion. 3, 16, 17 Reference lists of the studies identified by the above methods were examined. All authors of potentially eligible studies were asked at least twice to provide data sets with individual patient information (see Appendix for further information on data extraction).
Risk of bias
Risk of bias for all included studies was assessed independently (BL and KK). The Cochrane Guidelines on Systematic Reviews on Diagnostic Test Accuracy were followed, 18 and the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies *The appendix is available in the online version of this article, at http://www.ingentaconnect.com/content/iuatld/ijtld/2017/ 00000021/00000005/art00005 2) tool was adapted to assess the risk of bias 19 (Appendix).
Data analysis
Meta-analysis was performed using individual-level data provided by authors. For studies providing Xpert C T values for each of the probes, a mean C T value was calculated. For isolates with rpoB mutation, mean C T values were calculated disregarding the probe with a C T value of 0. Mean Xpert C T values for smear-positive and smear-negative, culture-positive samples were calculated. Linear regression was used to investigate the association between C T values and smear positivity, smear grading and days to culture positivity. ROC analysis, stratified by human immunodeficiency virus (HV) status, was performed to determine the optimal C T value, taking into account clustering by patient and study site. Sensitivity and specificity with corresponding 95% confidence intervals (CIs) were calculated for differing cut-off values. All analysis was conducted using Stata 13 (StataCorp, College Station, TX, USA).
RESULTS

Study selection
Individual patient data The last search was performed in February 2016. Of 918 unique citations identified, 92 were deemed potentially relevant for inclusion in the individual patient data meta-analysis (Figure 1 ; Appendix, information on all studies) and authors were contacted. Fourteen study teams provided anonymised individual-level data from 15 studies for the metaanalysis (Table 1) . 21, 25, 27, 29, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Descriptive systematic review on association between C T values and smear status Ten studies investigated the association between smear status and C T values (Figure 1) . 11, 20, 21, 26, [33] [34] [35] [36] [37] [38] [39] [40] Seven of the ten studies were conducted in subSaharan Africa, and HIV prevalence among study participants ranged from 3% to 60%. Two studies did not provide information on HIV prevalence. 27, 36 Overall studies were of moderate to good quality, although they did not always report on their efforts to minimise bias. Most, however, were consecutive or random collections of samples, and nearly all, except three, did report on the flow of patients in the study (Table 1) . 20, 34, 36 The mean C T values of smear-positive samples were significantly lower (difference of mean C T values 3-10) than smear-negative samples. 35, 36, 41 Two studies assessed the association between smear grade and C T values and found a moderate to good inverse correlation (Spearman correlation coefficient range 0.7-0.9). 21, 36 Three studies performed ROC analysis and proposed an optimal cut-off C T value for the detection of smear-positive samples. Cut-offs Xpert CT values to predict smear status in TB derived using Youden's index (aiming at optimising sensitivity and specificity) were estimated to be respectively 27.7, 27.1 and 27.5. 21, 33, 37 The corresponding sensitivity for smear positivity using these C T value cut-offs ranged from 82% to 98%. 21, 33, 37 One study performed an analysis stratified by HIV status, and reported an optimal cut-off of 26.7 for samples from HIV-infected and 28.8 for non-HIVinfected patients. 37 Meta-analysis of individual-level data Individual-level data from 14 studies and one unpublished data set were included (Table 1; see  Appendix for description of unpublished data  set) . 21, 25, 27, 29, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Collectively this amounted to 7511 respiratory samples from 4447 patients. A total of 1406 patients had at least one culture-positive sample, 1212 of whom had at least one Xpertpositive sample, 636 had two Xpert-positive samples and 11 patients more than three. The total number of Xpert-positive samples included in the meta-analysis was 1859. The majority of the samples were from males (64%); 20% of the samples were smearnegative, and among those patients with known HIV (44%) status, 14% were HIV-infected ( Table 2) .
The mean C T value for smear-positive samples was significantly lower (22.0, 95%CI 21.5-22.6) than for smear-negative samples (29.3, 95%CI 28.1-30.5) (Appendix). Regression analysis revealed a decrease in C T value of 7.4 (95%CI À8.1 to À6.8) for smearpositive samples, with 25% of the variability explained by smear status. Analysis adjusted for sex, age Figure 2A ). Including smear grade as a linear variable yielded a regression coefficient of À3.1 (95%CI À3.4 to À2.8).
C T value and days to culture positivity Data on days to culture positivity were provided for 1424 samples. A linear regression of C T value and days to culture positivity showed evidence of a positive association (P , 0.001). The average increase in C T value was 0.18 for each extra day to culture positivity (95%CI 0.12-0.24) in a linear regression accounting for clustering by participants and adjusting for HIV, sex, age and study location (n ¼ 776 ) ( Figure 2B and Table 3 ).
Receiver operator characteristic analysis ROC analysis, adjusted for study location and accounting for clustering by patient, was performed to determine the area under the curve (AUC) and sensitivity and specificity for specific C T value cutoffs ( Figure 3 ). The overall AUC was 0.85 (95%CI 0.82-0.87), and remained the same when stratified by HIV status. Sensitivity and specificity for different C T value cut-offs stratified by HIV status are shown in Table 3 . Overall, a C T value cut-off at 27.7 would provide a sensitivity of 85% (95%CI 83-87) and a specificity of 67% (95%CI 66-77). In non-HIVinfected individuals, the same cut-off would have a 21 performing the same regression analysis on 208 samples from all other studies, the b coefficient for smear-positive samples compared to smear-negative samples was À6.9 (95%CI À8.3 to À5.5).
sensitivity of 83% (95%CI 79-86) and a specificity of 62% (95%CI 51-71), while in HIV-infected patients sensitivity would be 79% (95%CI 70-85) and specificity 79% (95%CI 65-88). To raise sensitivity to 95% (95%CI 94-96), the overall cut-off would have to be set at 31.8, resulting in a specificity of 35% (95%CI 30-41) (Table 4 and Figure 3 ).
DISCUSSION
Key findings
This review confirms the consistent, strong association between Xpert C T values and the bacillary load, through both a descriptive review of the literature and a meta-analysis of 1859 samples. Three of 10 studies included in the descriptive review conducted ROC analysis and reported C T value cut-offs of between 27.1 and 27.7 for optimal specificity (48-79%) and sensitivity (82-98%). Data on 1859 Xpert-positive respiratory samples from 1212 patients were included in the meta-analysis. The mean difference in C T values between smear-positive and smear-negative samples was 7.4. The ROC curve showed good diagnostic accuracy (AUC 0.85).
Strengths and limitations
The strengths of this review include a broad search strategy across different databases without any restrictions with regard to language and setting. Despite our best efforts, only 14/92 potentially eligible studies and one previously unpublished data set could be included in the meta-analysis. While some studies could not be included due to the lack of C T values, authors of other studies presenting data on C T values and smear status were unable to provide individual-level data. [34] [35] [36] The data included in the meta-analysis thus presents a selection, and might be prone to bias. One study provided .50% of all samples, which might have disproportionately influenced our results. However, sensitivity analysis excluding this study revealed similar results. The overall quality of the included studies was moderate to good, and risk of bias within studies was low.
Interpretation of findings
The general association between Xpert C T values and bacillary load is not new, and mirrors what individual studies have shown. 11, 21 Our meta-analysis allows for detailed and context-dependent analysis of this relationship for programmatic purposes. The moderate diagnostic accuracy of C T values compared to smear in this meta-analysis, as well as different needs in contexts with varying prevalence of smear positivity, might preclude the use of C T values as a replacement for smear in every context.
Deciding which C T cut-off to use will differ according to the required objectives and context. To detect 95% of smear-positive patients, a cut-off of 31.8 would have to be chosen, resulting in a low (35%) specificity and lower positive predictive value. In the context of scarce resources, patients with the lowest C T value, such as 20.7, might be prioritised for isolation. A recent cost-effectiveness study from the United States suggested that the use of Xpert in guiding decisions on patient isolation could substantially reduce isolation time as well as costs. 42 In the context of contact tracing, C T cut-offs may be chosen according to resource availability. A C T value cut-off of 27.7 would result in 59% of individuals being labelled as 'highly infectious' in a setting where 50% of patients with pulmonary TB are smear-positive. The C T value cut-off would thus identify a similar number of highly infectious index cases as smear microscopy, and result in a similar number of contact tracing activities. However, 28% of these index cases identified by C T value cut-off would be smear-negative, and 15% of the index cases identified as less infectious would be smear-positive. The sensitivity of C T value cut-offs will always be less than 100%. However, smear positivity alone is itself an imperfect measure of infectiousness, 12, 43 and transmission from smear-negative, culture-positive index cases is well described. 44 C T values are generated in a consistent automated fashion, are less operator-dependent than smear microscopy, produce a timely available read-out, do not require any interpretation and are thus more objective. Whether smear status or Xpert C T values predict infectiousness more accurately remains to be shown in prospective controlled studies. With regard to treatment monitoring, C T values provide a theoretical advantage of being able to compare numerical values over time rather than comparing two broad categories. In this paper, we did not specifically assess C T values for their value in treatment monitoring. However, a multicentre trial conducted in sub-Saharan Africa failed to show any association between Xpert results and treatment outcomes in patients with drug-susceptible TB, despite good correlation between Xpert C T values and smear status. 38 It is therefore difficult at this point to judge the usefulness of C T values for serial testing of patients as part of treatment monitoring. 2 A limitation inherent to smear microscopy and Xpert is the inability to differentiate between viable and dead bacilli. This differentiation is particularly important in patients on treatment. This has been addressed in the context of the Xpert test that uses propidium monoazide. 20 C T values of samples treated with propidium monoazide were consistently lower than C T values of untreated samples. Further research is needed to assess whether Xpert, with or without propidium monoazide pretreatment, could substitute smear microscopy for the purpose of treatment monitoring.
In conclusion, this meta-analysis provides further evidence that Xpert C T values are strongly associated with smear status. However, the important question of whether Xpert C T values predict infectiousness, transmission and treatment response remains unanswered. The correlation between Xpert C T values and bacillary load is biologically plausible and supported by the results of this review. Given that mycobacillary burden on an individual level is linked to onward M. tuberculosis transmission, it may even be that aggregated Xpert C T values at a community level (akin to community mycobacterial load) could potentially be used as a marker of ongoing community transmission, a concept similar to community viral load in the context of HIV. 45 Conflicts of interest: DA reports grants from Cepheid (Sunnyvale, CA, USA) during the conduct of the study; DA also has a beacon patent pool with royalties paid. HAD reports grants from the Ministry of Higher Education of Malaysia, Putrajaya, Malaysia, during the conduct of the study. CMD is employed by the Foundation for Innovative New Diagnostics (Geneva, Switzerland), a non-profit organisation that collaborates with industry partners, including Cepheid, among others, for the development, evaluation and demonstration of new diagnostic tests for povertyrelated diseases. FIND has organisational firewalls in place to avoid any undue influence of industry on the work of FIND or the publication of evidence. MBM reports fees from Cepheid for being on a scientific advisory board and reagent support for the initial study. EBP reports non-financial support from Cepheid, outside the submitted work. The remaining authors have nothing to disclose. 
Information on the unpublished data set
The data set contains data on 170 successive samples of 170 patients from the National Reference Laboratory in Kyrgyzstan from 2013 and 2014. Only samples with information available on culture, microscopy and Xpert results were provided, in an anonymised manner. No information on HIV status or time to culture positivity was available. The data set was provided by G Kalmambetova, Head of the Laboratory. Xpert CT values to predict smear status in TB v 
R E S U M E N M A R C O D E R E F E R E N C I A:
La prueba Xpert w MTB/RIF es el método molecular de diagnóstico rá pido de la tuberculosis (TB) má s utilizado. El nú mero de ciclos de la reacción en cadena de la polimerasa a partir del cual se genera un producto detectable (ciclo umbral, C T ) se correlaciona con la cantidad de micobacterias en la muestra. O B J E T I V O: Investigar la asociación entre el valor del C T de la prueba Xpert y la calificación de la baciloscopia, mediante una revisión sistemá tica y el metaná lisis de datos a escala individual.
M É T O D O:
En una revisión sistemá tica descriptiva se incluyeron estudios sobre la asociación de los valores del C T y la calificación de la baciloscopia. Se solicitó a los autores de los estudios que comportaban resultados de baciloscopias, cultivos y pruebas Xpert que comunicaran los datos a nivel individual y se calcularon la curvas de eficacia diagnóstica. R E S U LTA D O S: En la revisión sistemá tica descriptiva se incluyeron 10 de las 918 citas de artículos. Se obtuvieron los datos individuales de 15 conjuntos de datos de estudios que podían ser pertinentes en el metaná lisis de datos individuales (7511 muestras de 4447 pacientes). En 1212 pacientes se observaron resultados positivos de la prueba Xpert de por lo menos una muestra respiratoria (1859 muestras en total). El aná lisis de la eficacia diagnóstica reveló un á rea bajo la curva de 0,85 (IC95% 0,82 a 0,87). Al adoptar valores límites del C T de 27,7 y de 31,8 se obtuvieron respectivamente sensibilidades de 85% (IC95% de 83 a 87) y 95% (IC95% de 94 a 96) y especificidades de 67% (IC95% de 66 a 77) y 35% (IC95% de 30 a 41) para las muestras con baciloscopia positiva. C O N C L U S I Ó N: El valor del C T de la prueba Xpert y la clasificación de la baciloscopia exhibieron una fuerte correlación. Sin embargo, la precisión diagnóstica de la prueba cuando se define un valor límite del C T de 27,7 o de 31,8 no remplazaría la baciloscopia. Queda por discernir cuá l de los dos datos, el valor del C T de la prueba Xpert o la baciloscopia, pronosticaría mejor la contagiosidad.
